Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric growth and sexual maturation evaluation with risperidone versus other atypical antipsychotics
2009-012003-26Phase 4Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of risperidone in schizophrenia, bipolar disorder (BD), Autism Spectrum Disorder (ASD) and 2 more (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Effects on child growth and sexual maturation. Started Jan 2010; status: terminated.
02
Drugs
risperidone
03
Conditions
schizophreniabipolar disorder (BD)Autism Spectrum Disorder (ASD)conduct disorder (CD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on 2009-012003-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012003-26.